Dissapointment for Genmab as phase III study is cut short
Genmab is forced to stop a phase III study with its oncology drug ofatumumab early following a planned interim analysis performed by an Independent Data Monitoring Committee.
BY STEFAN SINGH KAILAY
Danish biotech company Genmab said late Monday evening local time that it was forced to cut short a phase III study with oncology medicine ofatumumab as a treatmnent for follicular non-Hodgkin's lymphoma (NHL).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab’s sBLA for Arzerra granted Priority Review
For abonnenter
Gilead to use Genmab drug in cancer combo
For abonnenter
Novartis hails Genmab drug
For abonnenter
